J Gastric Cancer.  2021 Sep;21(3):258-267. 10.5230/jgc.2021.21.e25.

Clinical Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients with Comorbidities

• Natsagdorj E
• Kim SG
• Choi J
• Kang S
• Kim B
• Lee E
• Chung H
• Cho SJ

• KMID: 2526326
• DOI: http://doi.org/10.5230/jgc.2021.21.e25

Abstract

Purpose
As the rate of endoscopic resection for early gastric cancer (EGC) has increased in patients with comorbid diseases, it is necessary to elucidate the efficacy of endoscopic submucosal dissection (ESD) for EGC in patients with comorbidities. This study aimed to analyze the clinical outcomes of ESD for EGC in patients with comorbidities.
Materials and Methods
A total of 969 patients with 1,015 lesions who underwent ESD for EGC at Seoul National University Hospital between 2010 and 2014 were analyzed. The shortand long-term clinical outcomes were evaluated according to the comorbidity status.
Results
Comorbidities were observed in 558 patients (57.6%). The comorbidity group had a higher proportion of patients using antithrombotic agents (29.5% vs. 0.9%; P<0.0001). Although procedure-related complications (bleeding and perforation) were not significantly different between the two groups, the length of hospital stay was significantly longer (1.8 vs. 1.4 days, P=0.023), while survival was significantly shorter in the comorbidity group (5-year overall survival rate: 90.5% vs. 97.2%, P<0.0001; 5-year disease-specific survival rate: 97.9% vs. 100%, P=0.018; 5-year disease-free survival rate: 83.4% vs. 89.2%, P=0.007).
Conclusions
Gastric ESD can be performed in patients with comorbidities without increasing the risk of complications.

Keyword

Endoscopic submucosal dissection; Stomach neoplasms; Comorbidity